254 related articles for article (PubMed ID: 22703853)
1. Immunotherapies in neurologic disorders.
Graves D; Vernino S
Med Clin North Am; 2012 May; 96(3):497-523, x. PubMed ID: 22703853
[TBL] [Abstract][Full Text] [Related]
2. [Disease modifying drugs in multiple sclerosis and pregnancy].
Tur C; Tintoré M; Aguilera C
Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
[No Abstract] [Full Text] [Related]
3. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis.
Cocito D; Grimaldi S; Paolasso I; Falcone Y; Antonini G; Benedetti L; Briani C; Fazio R; Jann S; Matà S; Sabatelli M; Nobile-Orazio E;
Eur J Neurol; 2011 Dec; 18(12):1417-21. PubMed ID: 21819489
[TBL] [Abstract][Full Text] [Related]
4. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Johnston J; So TY
Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
[TBL] [Abstract][Full Text] [Related]
5. Immunologic therapy for secondary and primary progressive multiple sclerosis.
Myers LW
Curr Neurol Neurosci Rep; 2001 May; 1(3):286-93. PubMed ID: 11898531
[TBL] [Abstract][Full Text] [Related]
6. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
7. Immunologic therapy for relapsing-remitting multiple sclerosis.
MacLean HJ; Freedman MS
Curr Neurol Neurosci Rep; 2001 May; 1(3):277-85. PubMed ID: 11898530
[TBL] [Abstract][Full Text] [Related]
8. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome).
Frew JW; Murrell DF
Dermatol Clin; 2011 Oct; 29(4):607-12. PubMed ID: 21925005
[TBL] [Abstract][Full Text] [Related]
9. Newer long-term treatments for multiple sclerosis.
Pryse-Phillips W
Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
[No Abstract] [Full Text] [Related]
10. [Immunossupresive drugs in renal transplantation].
Baczkowska T; Durlik M
Pol Arch Med Wewn; 2004 Oct; 112 Spec No():99-120. PubMed ID: 15669207
[TBL] [Abstract][Full Text] [Related]
11. Myasthenia gravis: emerging new therapy options.
Sieb JP
Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
[TBL] [Abstract][Full Text] [Related]
12. Managing MS in a changing treatment landscape.
Duddy M; Haghikia A; Cocco E; Eggers C; Drulovic J; Carmona O; Zéphir H; Gold R
J Neurol; 2011 May; 258(5):728-39. PubMed ID: 21437661
[TBL] [Abstract][Full Text] [Related]
13. [Update on current care guidelines: multiple sclerosis].
Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
[TBL] [Abstract][Full Text] [Related]
14. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
15. The actual management of pemphigus.
Daniel BS; Murrell DF
G Ital Dermatol Venereol; 2010 Oct; 145(5):689-702. PubMed ID: 20930702
[TBL] [Abstract][Full Text] [Related]
16. [Biological treatment of multiple sclerosis].
Sørensen PS; Sellebjerg F
Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Clegg A; Bryant J; Milne R
Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
[No Abstract] [Full Text] [Related]
18. New and future therapies for lupus nephritis.
Appel GB
Cleve Clin J Med; 2012 Feb; 79(2):134-40. PubMed ID: 22301564
[TBL] [Abstract][Full Text] [Related]
19. New management algorithms in multiple sclerosis.
Sorensen PS
Curr Opin Neurol; 2014 Jun; 27(3):246-59. PubMed ID: 24759080
[TBL] [Abstract][Full Text] [Related]
20. [Choice of early and escalation treatment options for multiple sclerosis].
Linker RA; Kieseier BC
Nervenarzt; 2008 Oct; 79(10):1123-4,1126-8,1130-2 passim. PubMed ID: 18806985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
